GlassScriptPhysician profile
Larry Wayne Weathers
NPI 1770635047
$6,083.71
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $1,191 · 2021: $1,524 · 2022: $1,249 · 2023: $108 · 2024: $46.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $154.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $627.12 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $585.13 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $579.95 | 2019-2022 | |
| Abbott Laboratories | $540.26 | 2019-2024 | Amplatzer Amulet |
| Amgen INC. | $532.59 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $489.55 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.80 | 2019-2023 | Jardiance |
| Pfizer INC. | $448.20 | 2019-2022 | |
| Heartflow, INC. | $444.07 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.31 | 2019-2022 | |
| Edwards Lifesciences Corporation | $181.96 | 2019 | |
| Merck Sharp & Dohme LLC | $164.40 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $119.40 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $106.96 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $89.97 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $61.53 | 2021 | |
| Esperion Therapeutics, INC. | $60.27 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.98 | 2021-2023 | Eliquis |
| Chiesi USA, INC. | $47.49 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $45.37 | 2019-2022 | |
| Baxter Healthcare | $40.99 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $33.98 | 2019-2021 | |
| Davol INC. | $33.00 | 2020 | |
| Atricure, INC. | $31.05 | 2019 | |
| Livanova USA, INC. | $24.09 | 2019 | |
| Gilead Sciences, INC. | $22.81 | 2019 | |
| Philips North America LLC | $21.89 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2020 | |
| Glaxosmithkline, LLC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Weathers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.